Poor trial design leaves gene therapy death a mystery.
Wadman
Meredith
M
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D015316:Genetic Therapy / Q000379:methods / Q000401:mortality*; D006660:Histoplasmosis / Q000150:complications / Q000401:mortality; D006801:Humans; D009102:Multiple Organ Failure / Q000150:complications / Q000382:microbiology / Q000401:mortality; D012107:Research Design
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab